Status:
TERMINATED
A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C
Lead Sponsor:
Health Innovations, Frontier Research Institute
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this pilot study is to learn whether high doses of ascorbic acid (vitamin c), given intravenously to patients with chronic hepatitis due to infection with the genotype 1 version of the ...
Detailed Description
Hepatitis C virus (HCV) chronically infects 1% to 3% of the world's population, including about 3.9 million infected patients in the United States, with an estimated 36,000 new cases in the US each ye...
Eligibility Criteria
Inclusion
- hepatitis C, genotype 1
- failed treatment with interferon-alpha and ribavirin
- abstain from alcohol consumption for the duration of the study
Exclusion
- cirrhosis
- decompensated liver disease
- glucose6phosphate dehydrogenase deficiency
- AST or ALT more than 5 times upper limit of normal
- platelets less than 125,000
- diabetes mellitus
- alcohol and/or drug abuse within 1 year of screening
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01250743
Start Date
January 1 2009
End Date
June 1 2012
Last Update
February 18 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center, Department of Integrative Medicine
Kansas City, Kansas, United States, 66160